-

Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. EDT.

The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte

Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X, and Instagram. 

Contacts

Media
media@incyte.com

Investors
ir@incyte.com

Industry:

Incyte

NASDAQ:INCY
Release Summary
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Release Versions
English
$Cashtags
$INCY

Contacts

Media
media@incyte.com

Investors
ir@incyte.com

Social Media Profiles
Incyte/LinkedIn
@Incyte
More News From Incyte

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

WILMINGTON, Del.--(BUSINESS WIRE)--Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the EU for Adults with Moderate Atopic Dermatitis...

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates...
Back to Newsroom